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doi:10.1016/j.jtcvs.2007.05.044bjective: The role of matrix metalloproteinases and their tissue endogenous inhibitors
as been documented in abdominal aortic aneurysms, but few articles have investigated
heir role after thoracic aortic aneurysm treatment. Our report investigates matrix
etalloproteinases and tissue endogenous inhibitor-1 plasmatic changes in patients who
ave undergone endovascular aneurysm repair for descending thoracic aortic aneurysms
nd assesses their clinical significance.
ethods: Thirty-two patients with thoracic aortic aneurysms who underwent endo-
ascular aneurysm repair were compared with 25 healthy volunteers. Plasma matrix
etalloproteinase-3/matrix metalloproteinase-9 and tissue endogenous inhibitor-1
alues were determined by an enzyme-linked immunosorbent assay method at a
redetermined time interval.
esults: The preoperative levels of matrix metalloproteinases in the endovascular aneurysm
epair group were 3-fold and 2-fold higher than those in the control group (P .001 and .02,
espectively). Matrix metalloproteinase values normalized after endovascular aneurysm
epair, whereas patients experiencing endoleaks had higher matrix metalloproteinase values
nd matrix metalloproteinase-9/tissue endogenous inhibitor-1 ratio compared with the con-
rol group (P .003, .001, and .02, respectively, at 1-month follow-up). These values
ormalized with the resolution of the endoleak.
onclusions: Plasma matrix metalloproteinase values are increased in patients with
horacic aortic aneurysms, along with reduced tissue endogenous inhibitor-1 ex-
ression. Successful endovascular aneurysm repair results in values normalization,
hereas high levels persist in patients with endoleaks. The enzyme-linked immu-
osorbent assay test is a simple and reliable technique that is useful to assess the
fficacy of endovascular aneurysm repair and to detect endoleaks.
horacic aortic aneurysms (TAAs) are a serious and potentially lethal disease
with high mortality and morbidity rates.1 Even if atherosclerosis plays 
important role in the genesis of TAAs, their formation and progression are a
ultifactorial process involving both cellular and extracellular processes that have
ot been extensively examined.2
Matrix metalloproteinases (MMPs) are a group of proteases that play an impor-
ant role in the protein synthetic–lytic equilibrium of connective tissue. The extra-
ellular matrix (ECM) degradation in aneurysm tissue is in part caused by MMPs.
n addition, it has been demonstrated that the endogenous tissue inhibitor of
etalloproteinases (TIMP) plays a role in the modulation of MMP activity.3 MMP-3
nd MMP-9 are the most important and widespread MMPs in abdominal aortic
neurysm (AAA) wall tissue, and although their role in the destructive rearrange-
ent of the elastic aortic wall components has been well demonstrated in AAA
odels,4-8 few reports have demonstrated their role in TAAs.9-12 Moreover, althoughhe role of MMPs and TIMPs as a marker of successful aneurysm exclusion after
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A
CDndovascular aneurysm repair (EVAR) of AAAs has been
lucidated,5-7 no study to date has determined their chan
fter EVAR of TAAs and their influence on the clinical out-
ome of patients.
The aim of our report is 2-fold: (1) to investigate the
hanges of MMP-3, MMP-9, and TIMP-1 in the blood
lasma of patients who have undergone EVAR for descend-
ng TAAs and (2) to assess their clinical significance.
aterials and Methods
rom June 2003 to June 2005, 32 patients (group A) who under-
ent EVAR for TAA were compared with 25 healthy volunteers
ABLE 2. Matrix metalloproteinase-3, matrix metalloprote
nd matrix metalloproteinase-9/tissue inhibitor of metallop
Control group
(20 patients)
EVAR group
(16 patients)
End
(4
MP-3
Preoperative 136.0 73.5 392.2 148.2 37
Discharge 134.4 74.5 154.6 61.5 22
1 mo 133.8 73.6 152.1 61.6 32
3 mo 135.7 74.4 145.2 86.0 22
6 mo 134.4 73.2 146.8 87.9 18
MP-9
Preoperative 63.1 38.7 124.1 58.0 11
Discharge 64.8 39.6 97.3 57.7 12
1 mo 64.4 39.8 92.3 55.2 15
3 mo 63.8 40.0 70.4 46.2 13
6 mo 65.3 40.8 70.9 50.8 8
IMP
Preoperative 11.1 7.6 5.4 3.8
Discharge 11.2 8.0 8.1 4.8
1 mo 10.9 7.5 8.8 5.4
3 mo 11.2 7.8 12.5 7.9 1
6 mo 10.5 7.3 11.3 8.8 1
MP/TIMP
Preoperative 8.7 7.0 24.5 9.7 1
Discharge 8.8 6.9 14.4 8.4 2
1 mo 8.3 5.2 13.9 6.9 2
3 mo 8.1 6.8 6.3 1.2
6 mo 9.0 6.8 7.2 3.6
Abbreviations and Acronyms
AAA  abdominal aortic aneurysm
CT  computed tomography
ECM  extracellular matrix
ELISA enzyme-linked immunosorbent assay
EVAR  endovascular aneurysm repair
MMP matrix metalloproteinase
TAA  thoracic aortic aneurysm
TIMP  tissue inhibitor of metalloproteinasesVAR, endovascular aneurysm repair; TIMP, tissue inhibitor of metalloproteinas
26 The Journal of Thoracic and Cardiovascular Surgery ● Octogroup B). The 2 groups were matched for age and sex. Both
VAR and control groups were not on a regimen of statins,
cetylsalicylic acid, or angiotensin-converting enzyme inhibitors,
r any anti-inflammatory therapy that might affect MMP secretion.
ABLE 1. Clinical characteristics of control group and
ndovascular aneurysm repair group
linical variables
EVAR group
(n  32)
Control group
(n  25) P
ge, y 68.45 5.78 66.07 1.29 .07
ale 27 (84.4%) 19 (76.0%) .5
iabetes 9 (28.1%) 5 (20.0%) .6
ypertension 21 (65.6%) 14 (56.0%) .5
schemic heart disease 4 (12.5%) — .07
revious CABG 3 (9.4%) — .1
revious vascular surgery 3 (9.4%) — .1
enal insufficiency (creatinine
 1.5 mg/dL)
6 (18.7%) — .2
hronic obstructive pulmonary
disease
13 (40.6%) 4 (16.0%) .08
SA score 1.72 0.5 1.21 0.4 .0005
VAR, Endovascular aneurysm repair; CABG, coronary artery bypass graft;
SA, American Society of Anesthesiologists. Data are reported as mean
tandard deviation or n (%).
-9, tissue inhibitor of metalloproteinase-1 plasma levels,
inase-1 ratio at five different time points
group
ents)
P value
EVAR vs control
P value
endoleak vs
control
P value
endoleak vs
EVAR
14.4 .001 .001 NS
15.5 NS .001 .01
35.0 NS .003 .002
34.4 NS .04 NS
6.8 NS NS NS
29.4 .02 .02 NS
19.7 NS .01 NS
15.6 NS .001 .02
32.2 NS .02 .02
27.2 NS NS .04
1.5 .04 NS NS
2.5 NS NS NS
2.6 NS NS NS
6.1 NS NS NS
3.8 NS NS NS
3.6 .003 .005 NS
8.4 .01 .008 .01
4.7 .01 .02 .01
2.3 NS NS .006
5.3 NS NS NSinase
rote
oleak
pati
9.5
8.3
6.0
4.3
8.0
3.6
6.0
0.0
0.3
3.8
5.9
8.8
7.5
4.5
4.8
5.0
2.1
2.2
9.7
8.7es; NS, not significant.
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A
CDpproval for the study was obtained from the institutional review
oard, and informed consent was granted by each patient. In
ontrol group B, the absence of aortic and/or peripheral vascular
isease was assessed by spiral computed tomography (CT) scan
nd Color-Duplex scanner. Demographic and clinical data of the
atients enrolled in the study are listed in Table 1. Group 
nly atherosclerotic TAAs; patients with thoracic aorta dissection,
ransection, or Marfan syndrome were excluded.
The diagnosis of TAAs in group A was obtained by CT scan.
valuation of aneurysm length, diameter, quality, dimension of the
roximal and distal necks, diameter of the access vessels, and
resence or absence of mural thrombus at the necks were assessed.
isk assessment criteria were evaluated according to the American
ociety of Anesthesiologists score.13
Blood samples for plasma MMP-3, MMP-9, and TIMP-1 val-
es determination were collected from each patient of group A by
enous puncture into an ethylenediamine tetraacetic acid blood-
ollection tube before the stent-graft procedure, at hospital dis-
harge, and at 1, 3, and 6 months of follow-up. In control group B,
lood samples were obtained at days 1 and 7, and at 1, 3, and 6
onths later. Samples were centrifuged (3000g for 20 minutes),
nd the supernatant was carefully removed and stored at 80°C,
nd then thawed at room temperature just before the assays.
lasma MMP and TIMP-1 concentrations were measured by using
quantitative sandwich enzyme-linked immunosorbent assay
ELISA) test (Amersham International, Little Chalfont, UK), ac-
ording to the manufacturer’s guidelines. All samples were mea-
Figure 1. MMP-3 plasma value concentrations befor
significant; †<.05; ‡<.01; §<.001. EVAR, Endovascularured as duplicates; the mean was calculated for data analysis and m
The Journal of Thoracicad
atched with the normal plasma values of MMP-3, MMP-9, and
IMP-1 with an ELISA test (ie, 12.5–350 ng/mL, 0.25-200 ng/mL,
nd 0.15-30 ng/mL, respectively).
Eligibility criteria for EVAR were aneurysm diameter more
han 6.0 cm and/or documented aneurysm growth more than 0.5
m in the last 12 months. Exclusion criteria for EVAR candidates
ere proximal aortic neck diameter larger than 4.4 cm or length of
onaneurysmal aorta from the origin of the left subclavian artery to
he proximal attachment site less than 1.5 cm. Details of the
ndovascular procedure have been reported.14
All patients had a Talent stent-graft (Medtronic Inc, Santa
osa, Calif) with a mean of 2.2  0.7 stent-graft per patient.
rimary procedural success was defined as the absence of death or
urgical conversion, exclusion of aneurysm or transected tract,
cclusion of thoracic tear, and technically successful deployment
f the endoprosthesis at the intended target location.
Early mortality and morbidity were considered as events oc-
urring on the same hospital admission or within 30 days of the
rocedure. Late mortality included all deaths after 30 days. Any
eath that occurred suddenly or could not be related to other causes
as classified as due to aortic disease.
Endoleaks, a specific complication of EVAR procedure, are
efined as blood flow outside the lumen of the stent graft but
ithin the aneurysm sac and were classified as early, when de-
ected immediately after the endovascular procedure, and late,
hen developed de novo during the follow-up.
The follow-up ranged from 12 to 36 months (mean 24.5  7.3
during follow-up after stent-graft placement. *Not
rysm repair; MMP, matrix metalloproteinase.e and
aneuonths) and included a clinical examination and standard labora-
and Cardiovascular Surgery ● Volume 134, Number 4 927
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A
CDory test with MMP and TIMP-1 plasma level determinations.
horacic and abdominal aorta CT scans, to detect the efficacy of
he EVAR, were performed at the patient’s discharge and at 1 and
months later.
tatistical Analysis
ll data are presented as mean  standard deviation. The
earson chi-square test was used to assess differences for
linical variables between the EVAR and control groups. A
ann–Whitney U test was used to assess differences between
he groups for the same variable, and repeated-measures anal-
sis of variance was used to assess the differences between and
ithin the groups at different times. Univariate linear regres-
ion analysis and Pearson correlation coefficient (r) were used
o identify any significant correlation between MMP and
IMP-1 plasma levels and aneurysmal maximum diameters.
ata were analyzed by the Statistical Package for the Social
ciences 12.01 for Windows (SPSS Inc, Chicago, Ill).
esults
here were no hospital deaths. EVAR was successfully
erformed in all patients in accordance with the previ-
usly defined criteria. There were no cases of paraplegia
r neurologic complications. The mean procedure time
as 110.6  27.5 minutes (range 72–175 minutes), loss
f blood was minimal, and no patient required any trans-
usion. The mean length of hospital stay was 5.1  1.2
Figure 2. MMP-9 plasma value concentrations befor
significant; †<.05; ‡<.01; §<.001. EVAR, Endovascularays (range 4 –10 days). M
28 The Journal of Thoracic and Cardiovascular Surgery ● OctoThere were no late deaths. At the 1-month CT scan, 4
ndoleaks were identified in 4 patients (12.5%): 2 patients
ad a proximal type I endoleak (6.2%), 1 patient required a
econdary EVAR 1 month later and the other resolved
pontaneously within 6 months; the remaining 2 patients,
ith type II endoleaks caused by retrograde flow from
ntercostal arteries, showed flow reduction and no expan-
ion of the aneurysmal sac at the later follow-up. After stent
raft placement and during follow-up, plasma value concen-
rations of MMP-3 and MMP-9, and MMP-9/TIMP-1 ratio
ignificantly decreased in patients showing no endoleak com-
ared with preoperative values (repeated-measures analysis of
ariance test, P  .001, .001, and .01, respectively), whereas
IMP-1 plasma values significantly increased (P  .001),
specially in patients with endoleaks (P  .001). At the same
ime, these changes were not significant in patients with
ndoleaks.
In control group B, plasma concentrations of MMP-3,
MP-9, and TIMP-1 were not correlated to age (rs 
0.196-0.109) and were not different between female and
ale controls (Mann–Whitney U test, P  not significant).
ontrol group B data were then compared with the results of
atients with descending TAAs who had undergone EVAR
group A). The results are summarized in Table 2. The 
reoperative plasma values for MMP-3, MMP-9, and
during follow-up after stent-graft placement. *Not
rysm repair; MMP, matrix metalloproteinase.e and
aneuMP-9/TIMP-1 ratio in group A were significantly higher
ber 2007
t
r
f
.
b
.
s
M
a
g
M
m
p
c
a
n
p
c
D
T
t
r
b
e
a
r een
i
i
m
M
l
r nt
i sm
f
i
w
4
w
e
a
s
a
r
o
r
a
M
o
a
Monaco et al Surgery for Acquired Cardiovascular Disease
A
CDhan those in group B (P  .001,  .02, and  .003,
espectively), whereas the mean preoperative plasma value
or TIMP-1 was significantly lower than in group B (P 
04). At 1 month follow-up, only the MMP-9/TIMP-1 ratio
etween the 2 groups reached statistical significance (P 
01). At the 6-month follow-up all values studied were
imilar in both groups.
The 4 patients with endoleaks showed an increase of
MP-3 and MMP-9 at the 1-month follow-up (P  .002
nd .02 vs group A, respectively; P  .003 and  .001 vs
roup B, respectively), which slightly persisted only for
MP-9 at the 6-month follow-up, when a clinical improve-
ent of the endoleaks was also observed (P  .04). In
atients with endoleaks, the MMP-9/TIMP-1 ratio increased,
ompared with both EVAR and control groups, at discharge
nd at 1 month (P  .008 and .02, respectively), reaching
ormal values at 6 months. The plasma value concentrations
reoperatively, after EVAR, and during follow-up, and in
ontrol patients, are shown in Figures 1, 2, 3, and 4.
iscussion
he main cause of descending TAAs is atherosclerosis, and
he pathogenesis of such atherosclerotic aneurysms may
esemble that of AAAs. The aortic wall resists dilatation
ecause of the strength of its ECM components, notably
lastin and collagen. The MMPs, degrading the ECM, play
Figure 3. TIMP-1 plasma value concentrations before and
†<.05; ‡<.01; §<.001. EVAR, Endovascular aneurysm repcentral role in the pathogenesis of atherosclerotic aneu- (
The Journal of Thoracicysms.5 Several members of the MMP family have b
mplicated in the pathogenesis of aortic aneurysms, includ-
ng stromelysin (MMP-3) and gelatinase B (MMP-9). In
ouse models of atherosclerosis, macrophage-derived
MPs (MMP-3, 9, and 12) triggered elastolysis and col-
agenolysis, resulting in media destruction and thus aneu-
ysm formation.15,16 MMP-3 and MMP-9 are well prese
n the wall of AAAs,7,8 and the role of MMP-9 in aneury
ormation has been addressed.10,17 MMP-9, released from
nflammatory cells, is significantly elevated in the aneurysm
alls; the levels of MMP-9 messenger RNA expression are
-fold higher in large aneurysms (5.0–6.9 cm) compared
ith small aneurysms (3.0 – 4.9 cm).18
An imbalance between MMPs and TIMPs may tip the
quilibrium toward matrix degradation, thus influencing
neurysm development. Tamarina and colleagues,19 who
tudied messenger RNA levels for MMPs and TIMPs in
neurysms and normal aorta, demonstrated the predominant
ole of MMP-9 and TIMP-1 in the aneurysm group. More-
ver, TIMP-1–deficient mice, in which experimental aneu-
ysm formation was induced, had an increase in abdominal
nd thoracic aneurysm size.20,21
We prospectively studied the changes in MMP-3,
MP-9, and TIMP-1 plasma levels in a consecutive series
f patients with TAAs who had undergone EVAR (group A)
nd matched them with a control group of healthy patients
ng follow-up after stent-graft placement. *Not significant;
IMP, tissue inhibitor of metalloproteinases.duri
air; Tgroup B). Moreover, we studied the MMP-9/TIMP-1 ratio
and Cardiovascular Surgery ● Volume 134, Number 4 929
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A
CDs a reliable marker of shifting from an overall proteolytic
tate to a more homeostatic one. The increased preoperative
lasma levels of MMP-3 and MMP-9 that we observed in
roup A compared with group B may confirm the relation
etween active ECM catabolism and aneurysm progression.
hese data, widely known for AAAs, have scarcely been
xamined in patients with descending TAAs.10-12 Our re-
ults seem to confirm the similar pathophysiology for AAAs
nd TAAs and may prove useful in following patients
reated by EVAR. To our knowledge, this report is the first
o demonstrate changes in MMP-3 and 9 and TIMP-1
lasma levels in patients affected by descending TAAs who
ere successfully treated by EVAR and its clinical
ignificance.
In agreement with other studies demonstrating a de-
rease in MMP levels after endovascular or surgical
epair,6,7 our study demonstrated an early decrease 
MP-3 and an increase of TIMP-1 levels, with the
MP-9 decreasing more gradually. All of these values
eached normality at the 6-month follow-up. We hypoth-
sized that this difference in MMP-3 and MMP-9 de-
rease is the result of the postimplantation syndrome, as
ccurred in 5 of our patients, or the unspecific inflam-
atory reaction that always occurs after TAA surgery
both endovascular or open). Recently, Barbour and col-
Figure 4. MMP-9/TIMP-1 ratio before and during follo
‡<.01; §<.001. EVAR, Endovascular aneurysm repair;
metalloproteinases.eagues22 induced TAA formation in mice and demon- a
30 The Journal of Thoracic and Cardiovascular Surgery ● Octotrated a biphasic changes in MMPs, with persistent high
evels of MMP-9 in the late-phase response ascribed to
hronic inflammatory reaction.
EVAR for descending TAAs has become a consolidated
rocedure, improving on short- and mid-term results of
raditional surgical repair.23 Endoleak is a well-known com-
lication of EVAR, and close postoperative surveillance
nd early endoleak management are critical to determine the
ong-term success of EVAR. Patients are usually followed
p with serial CT scans,24 with significant increase in cos
nd radiation exposure. CT imaging alone is not always
dequate in the clinical decision-making process, because
he evaluation of only the aneurysmal diameter in the pres-
nce of an endoleak cannot exactly predict the outcome
fter endovascular TAA repair.
We found a relationship between the plasma MMP ex-
ression and the presence of an endoleak, and observed that
MP and TIMP-1 plasma levels follow the clinical pattern
f patients with an endoleak. In patients with an endoleak,
MP and TIMP-1 plasma levels normalize at the 3- and
-month follow-ups when adequate sealing, spontaneous
esolution, and/or reduction of both type I and II endoleaks
linically occur. On the contrary, a persistence or an in-
rease in MMP levels after EVAR may represent ineffective
neurysm exclusion. For this reason, we think that MMP
after stent-graft placement. *Not significant; †<.05;
, matrix metalloproteinase; TIMP, tissue inhibitor ofw-up
MMPnd TIMP-1 assays in patient with endoleaks may be useful
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A
CDn avoiding expensive CT scan control, and an increase in
lasma levels should indicate immediate treatment of the
ndoleaks. The MMP-9/TIMP-1 ratio, expression of protein
ynthetic–lytic equilibrium, seems to be a more accurate
arker, with a trend reflecting the clinical outcome of
atients with endoleaks.
Our data are preliminary and based on a small group of
atients with endoleaks after EVAR. To obtain meaningful
ata, more patients with endoleaks are necessary, but this
omplication rarely occurs in experienced centers.25
onclusions
lthough our study involved a small sample of patients and
ow statistical power, it confirms that plasma MMP-3 and
MP-9 values are increased in patients with TAAs, along
ith reduced TIMP-1 expression. MMP plasma level deter-
ination could be used to monitor the success of therapeutic
trategies for the treatment of TAAs: EVAR leads to plasma
alue normalization of these enzymes, whereas abnormally
igh levels are found in patients with endoleaks. The ELISA
est is a simple, readily available, and reliable technique that
ay be used both to assess the efficacy of EVAR and to
etect endoleaks, thus avoiding expensive serial CT scan
ontrol. Further studies are necessary before drawing pre-
ise conclusions.
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